ClinicalTrials.gg
Active, not recruitingNCT05180461Updated Mar 5, 2024

Emodepside Phase II Trial for Treatment of Onchocerciasis

A Phase 2 interventional study of emodepside and matching placebo of emodepside in Onchocerciasis, sponsored by Drugs for Neglected Diseases. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Drugs for Neglected Diseases · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
578
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.

Read the detailed description

There is an urgent need for a macrofilaricidal drug targeting the adult stage of Onchocerca volvulus, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA) programs.

Emodepside is a promising drug candidate to kill the adult and sexually mature Onchocerca volvulus. Emodepside was shown to be macrofilaricidal and microfilaricidal against a variety of filarial nematodes in non-clinical studies, and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).

Three Phase I trials of emodepside with single or multiple doses of emodepside have been conducted in healthy Caucasian men. The results are encouraging and support continuation of the clinical development programme of emodepside as treatment for onchocerciasis. One of these trials also enabled the selection of a field-adapted tablet formulation, suitable for use in countries endemic for onchocerciasis.

The present trial is designed in a stepwise approach starting with a proof of concept part, which is further subdivided in steps to investigate the safety, tolerability and pharmacokinetics of emodepside in the target population - Part 0 (pilot group), followed by investigations of the safety of emodepside in low and high-microfilaria carriers - Part 1a, and the dose-response relationship for efficacy of emodepside compared to placebo in microfilaria-positive patients - Part 1b. This approach allows to maximize the information regarding the safety of emodepside in the target population and to establish a dose range, in which emodepside is efficacious. Based on the information obtained from Parts 0 and 1, up to two efficacious dose regimens will be selected to carry forward into the confirmatory, active-controlled Part 2 of the trial, which will investigate the superiority of emodepside over ivermectin assessed using a clinically relevant endpoint, i.e. long-term absence of microfilariae at month 24.

02

Conditions studied

  • Onchocerciasis

Keywords

  • Helminthiasis
  • Filariasis
  • Parasitic diseases
  • Nematode Infections
  • Neglected tropical diseases
  • Skin Diseases, Parasitic
  • Skin Diseases, Infectious
  • River blindness
  • Anthelmintics
  • Anti-Infective Agents
  • Antinematodal Agents
  • Skin diseases
  • Anti-parasitic agents
  • Octadepsipeptide (cyclic depsipeptide)
03

In context

Onchocerciasis

35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.

This study's planned enrollment of 578 is above the median of 216 across 26 interventional studies indexed under Onchocerciasis.

Browse Onchocerciasis studies →

Lead sponsor

Drugs for Neglected Diseases is the lead sponsor of 58 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Part 1:

  1. Written, signed (or thumb-printed) and dated , after having the opportunity to discuss the study with the Investigator or a delegate.
  2. Men and women with Onchocerca volvulus infection, 18 to 65 years of age inclusive at time of Screening,

    1. Presence of at least 1 excisable subcutaneous nodule/onchocercoma detected on palpation
    2. O. volvulus infection diagnosed by skin snip method: documented mf-positivity on skin assessment on at least 2 out of 4 skin snips.

      • i. For Part 0: subjects with low microfilarial load, skin microfilarial density > 0 and \< 10 microfilariae/mg and without ocular involvement
      • ii. For Part 1a:

        • In groups with low microfilarial load, skin microfilarial density > 0 and \< 10 microfilariae/mg and without ocular involvement;
        • In groups with high microfilarial load, skin microfilarial density ≥ 10 microfilariae/mg with or without ocular involvement (only in anterior segment) or skin microfilarial density > 0 and \< 10 microfilariae/mg and with ocular involvement (only in anterior segment), which must include microfilariae in the eye, i.e. onchocercal corneal opacities alone are not acceptable.
      • iii. For Part 1b:

        • positive for microfilariae
  3. Body weight at Screening ≥ 40 kg
  4. For women of , acceptance of the requirement to use a highly effective form of effective from Day 0 until at least 3 months after the final intake of IMP (Month 4 visit). Choice of birth control method must be clearly documented.

Exclusion Criteria for Part 1:

  1. Participation in any studies other than purely observational studies within 3 months prior to Screening or during the study, or within 5 times the half-life of the drug in the previous clinical trial, whichever is longer (time calculated relative to final intake in previous trial) or currently in the follow-up period for any clinical trial.
  2. Any vaccination within 4 weeks prior to IMP administration.
  3. Acute infection and/or febrile illness requiring therapy within 14 days prior to IMP administration.
  4. Administration of medication or herbal therapies as follows:

    1. Administration of any medication (with the exception of diclofenac, paracetamol, ibuprofen and aspirin) or herbal preparation within 14 days prior to IMP administration, or medicine given regularly for an existing condition;
    2. The following antifilarial therapies, or medication that may have an antifilarial effect:

      • i. ivermectin; ≤ 6 months prior to IMP administration and / or
      • ii. doxycycline; ≤ 1 year prior to IMP administration: more than 2-week course and / or
      • iii. moxidectin; ≤ 2 years prior to IMP administration.
    3. Other preventive chemotherapy, e.g. as part of an MDA programme within 14 days prior to IMP administration.
  5. Presence of any medical condition at Screening: including, but not limited to diabetes type 1 or 2; past or current history of neurological or neuropsychiatric disease or epilepsy; sickle cell disease; known (HIV) infection, disclosed by review of medical history or concomitant medication.
  6. Presence of abnormal physical findings or laboratory values at Screening that could interfere with the objectives of the trial or the safety of the subject, in the opinion of the Investigator.
  7. Clinically significant history of cardiac abnormality, and/or relevant pathological abnormalities on electrocardiography at Screening, such as atrioventricular block (PR interval above 240 msec), or prolongation of the QRS complex over 120 msec or over 450 msec (QTcB or QTcF).
  8. Blood pressure and heart rate in the supine position at Screening, outside one or more of the ranges 90-140 mmHg systolic, 60-90 mmHg diastolic; heart rate 45-100 beats/min.
  9. Symptoms of orthostatic hypotension at Screening, considered clinically significant in the opinion of the Investigator.
  10. History of drug or alcohol abuse.
  11. Use of alcohol or drugs of abuse within 48 hours before IMP administration.
  12. Abnormal laboratory results at Screening, defined as (based on the reference laboratory test ranges for the study*):

    1. White blood cell count \< 3.0 x 109/L
    2. Neutrophils \< 1.0 x 109 /L
    3. Lymphocytes \< lower limit of normal (LLN)*
    4. \< 11 g/dL
    5. /serum glutamic oxaloacetic transaminase (AST/SGOT) and/or alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT > 2 x (ULN*) and/or > 1.5 ULN*
    6. Fasting glucose > ULN*
    7. Potassium \< LLN*
    8. Serum creatinine > ULN* and estimated (using the Modification of Diet in Renal Disease equation) \< 60 mL/min
    9. Any other abnormal laboratory result corresponding to Grade 2 or above in the study grading criteria, or abnormalities considered significant in the opinion of the Investigator.
  13. History of severe drug allergy, non-allergic drug reactions, severe adverse reaction to any drug, or multiple drug allergies.
  14. Known to any ingredient of the IMP, including the active ingredient emodepside, or to ivermectin, or to any medication used during the study (e.g. for eye examinations).
  15. Blood donation within 8 weeks prior to Screening or blood transfusion received within 1 year before Screening.
  16. Current hyperreactive onchodermatitis or severe manifestations due to onchocerciasis.
  17. Coincidental infection with other endemic filarial parasites based on laboratory tests at Screening (Wuchereria bancrofti, Mansonella spp.).
  18. Coincidental infection with Loa loa based on medical history or positive test at Screening.
  19. In groups intended to include subjects without ocular involvement: ocular microfilariae or onchocercal eye lesions, assessed at Screening.
  20. Ophthalmological history or conditions that could make the ocular examination difficult or represent a risk for the safety of the subject in the opinion of the Investigator, assessed at Screening, including the following (subjects will be excluded if any of the criteria are met for either eye):

    1. Ocular disease including inflammatory eye disease, uveitis, glaucoma or evidence of retinal cysticercosis;
    2. History of surgery for glaucoma and/or cataract;
    3. Evidence of corneal or conjunctival damage, with or without ocular symptoms (except corneal opacities in groups intended to include subjects with ocular involvement);
    4. Evidence of an increased risk of acute glaucoma, based on examination of anterior chamber.
    5. Evidence of ocular media opacity, including lens opacity and vitreous opacities, that make difficult ocular examination in the opinion of the Investigator;
    6. Evidence of retinal or optic nerve pathology (including age-related macular degeneration (AMD));
    7. Visual impairment of best corrected or pinhole visual acuity worse than 6/18 metres, and/or visual field defect of grade 3 (on frequency doubling technology (FDT) or worse; and/or - where ocular coherence tomography (OCT) is used - severe retinal nerve fibre layer thinning in the superior and inferior quadrant analysis on OCT of the optic nerve with a corresponding visual field defect of grade 2 (on FDT) or worse on the same eye; ; or blindness;
    8. Any microfilariae identified in the posterior segment of the eye or more than 50 microfilariae in the anterior segment.
  21. Unwilling to remain within the clinical research ward for the Admission Period (for Part 0 and Part 1a), or in or nearby the clinical research ward for the in-house period (for Part 1b) or unwilling to comply with the house rules of the clinical research ward.
  22. Any other past or current condition that the Investigator feels would exclude the subject from the study or that places the subject at undue risk.
  23. For women of child-bearing potential (WOCBP): pregnancy (determined by date of last menstrual period and serum pregnancy test prior to first intake of IMP), or breastfeeding.
  24. Unwilling or unable to comply with the requirements of the study protocol for the entire duration of the study, in the opinion of the Investigator.
  25. Unable to participate in the study as per local law, if applicable.

Inclusion Criteria for Part 2:

  1. Written, signed (or thumb-printed) and dated informed consent, after having the opportunity to discuss the trial with the Investigator or a delegate.
  2. Men and women with Onchocerca volvulus infection, 18 to 65 years of age inclusive at time of Screening.

    1. Presence of at least 1 excisable subcutaneous nodule/onchocercoma detected on palpation.
    2. Onchocerca volvulus infection diagnosed by skin snip method: documented mf-positivity on skin assessment on at least 2 out of 4 skin snips.
  3. Body weight ≥ 40 kg at Screening.
  4. For women of child-bearing potential, acceptance of the requirement to use a highly effective form of birth control effective from Day 0 until at least 3 months after the final intake of IMP (Month 4 visit). Choice of birth control method must be clearly documented.

Exclusion Criteria for Part 2:

  1. Participation in any studies other than purely observational studies, within 3 months prior to Screening, and during the study, or within 5 times the half-life of the drug tested in the previous clinical trial, whichever is longer (time calculated relative to last dose in the previous clinical trial) or is currently in the follow-up period for any clinical trial, or received emodepside as part of a previous clinical trial.
  2. Any vaccination within 4 weeks before IMP administration.
  3. Acute infection and/or febrile illness requiring therapy within 14 days prior to IMP administration.
  4. Administration of medication or herbal therapies as follows.

    1. Administration of any medication (with the exception of diclofenac, paracetamol, ibuprofen and aspirin) or herbal preparation within 14 days prior to IMP administration, or medicine given regularly for an existing condition, except with the approval of the Principal Investigator;
    2. The following antifilarial therapies, or medication that may have an antifilarial effect:

    i. ivermectin; ≤ 6 months prior to IMP administration and / or ii. doxycycline; ≤ 1 year prior to IMP administration: more than 2-week course and / or iii. moxidectin; ≤ 2 years prior to IMP administration. c. Other preventive chemotherapy, e.g. as part of an MDA programme within 14 days prior to IMP administration, except with the approval of the Principal Investigator.

  5. Presence of any of the following at Screening that could interfere with the objectives of the trial or the safety of the subject, in the opinion of the Investigator:

    1. Abnormal physical examination or laboratory finding;
    2. Any clinically significant medical condition. Including, but not limited to diabetes type 1 or 2, significant liver or cardiovascular disease, current or previous neurological or neuropsychiatric disease or epilepsy, active infection, sickle cell disease, known human immunodeficiency virus (HIV) infection, disclosed by review of medical history or concomitant medication.
  6. Recent history of drug or alcohol abuse (within 6 months prior to IMP administration).
  7. Use of alcohol or drugs of abuse within 24 hours prior to IMP administration.
  8. Abnormal laboratory results at Screening, defined as (based on the reference laboratory test ranges for the study*):

    1. Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and/or alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT > 2 x upper limit of normal (ULN*) and/or bilirubin > 1.5 ULN
    2. Serum creatinine > ULN* and estimated glomerular filtration rate (using the Modification of Diet in Renal Disease equation) \< 60 mL/min
  9. History of severe drug allergy, non-allergic drug reactions, severe adverse reaction to any drug or multiple drug allergies.
  10. Current hyperreactive onchodermatitis.
  11. Known hypersensitivity to any ingredient of the IMPs, including the active ingredient emodepside, or to ivermectin, or to any medication used during the study (e.g. for eye examination).
  12. Blood donation within 8 weeks prior to Screening.
  13. Coincidental infection with other endemic filarial parasites based on laboratory tests at Screening (Wuchereria bancrofti, Mansonella spp.)
  14. Coincidental infection with Loa loa based on medical history or positive test at Screening.
  15. Ophthalmological history or conditions that could interfere with the objectives of the trial or compromise the safety of the subject in the opinion of the Investigator, assessed at Screening, including the following (subjects will be excluded if any of the criteria are met for either eye):

    1. Inflammatory eye disease, glaucoma, severe uveitis, evidence of retinal cysticercosis;
    2. History of surgery for glaucoma;
    3. Severe keratitis, and/or cataracts that interfere with visualisation of the posterior segment of the eye;
    4. Evidence of an increased risk of acute glaucoma, based on examination of anterior chamber;
    5. Evidence of ocular media opacity, including lens opacity and vitreous opacities, that make difficult ocular examination in the opinion of the Investigator;
    6. Evidence of retinal or optic nerve pathology (including age-related macular degeneration (AMD));
    7. Severe visual impairment (best corrected or pinhole visual acuity worse than 6/60 metres), severe reduction of peripheral visual fields (greater than grade 3 on frequency doubling technology (FDT)) or blindness;
    8. Any microfilariae identified in the posterior segment of the eye or more than 50 microfilariae in the anterior segment.
  16. Any other past or current condition that the Investigator feels would exclude the subject from the study or place the subject at undue risk.
  17. For women of child-bearing potential (WOCBP): pregnancy (based on date of last menstrual period, and pregnancy test prior to first intake of IMP) or breastfeeding.
  18. Unwilling or unable to comply with the requirements of the study protocol for the entire duration of the study, in the opinion of the Investigator.
  19. Unable to participate in the study as per local law, if applicable.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
578 participants (estimated)

Study arms

  • Experimental
    Part 0 Pilot group emodepside 15mg Once a day (OD) 1 day

    emodepside tablets 15 milligrams once a day for 1 day

    Drug: emodepside

  • Experimental
    Part 1 emodepside 30mg OD 1 day

    emodepside tablets 30 milligrams once a day for 1 day

    Drug: emodepside

  • Experimental
    Part 1 emodepside 15mg OD 7 days

    emodepside tablets 15 milligrams once a day for 7 days

    Drug: emodepside

  • Experimental
    Part 1 emodepside 15mg OD 14 days

    emodepside tablets 15 milligrams once a day for 14 days

    Drug: emodepside

  • Experimental
    Part 1 emodepside 15mg twice a day (BID) 10 days

    emodepside tablets 15 milligrams twice a day for 10 days

    Drug: emodepside

  • Placebo comparator
    Part 1 placebo

    matching placebo of emodepside tablets

    Drug: matching placebo of emodepside

  • Experimental
    Part 2 emodepside dose regimen A

    emodepside tablets, dose regimen A selected from regimens tested in Part 1

    Drug: emodepside · Drug: matching placebo of ivermectin

  • Experimental
    Part 2 emodepside dose regimen B

    emodepside tablets, dose regimen B selected from regimens tested in Part 1

    Drug: emodepside · Drug: matching placebo of ivermectin

  • Active comparator
    Part 2 ivermectin

    ivermectin, single oral dose of 150 micrograms per kilogram by weight

    Drug: matching placebo of emodepside · Drug: ivermectin

Interventions

  • emodepside tablet

    Also known as: BAY 44-4400

  • Drugmatching placebo of emodepside

    emodepside matching placebo tablet

  • ivermectin tablet (overencapsulated for blinding)

    Also known as: Mectizan, Stromectol

  • Drugmatching placebo of ivermectin

    matching placebo of overencapsulated ivermectin tablet

06

What researchers measure

Primary outcomes

  1. Part 1 - absence (or presence) of live female adult worms with normal embryogenesis

    Absence (or presence) of live female adult worms with normal embryogenesis, assessed by histological examination of nodules collected on nodulectomy

    Time frame: 12 months

  2. Part 1 - absence (or presence) of skin microfilariae (co-primary outcome)

    Absence (or presence) of skin microfilariae across four skin snips

    Time frame: 12 months

  3. Part 2 - absence (or presence) of skin microfilariae

    Absence (or presence) of skin microfilariae, assessed across all skin snips in a participant

    Time frame: 24 months

Secondary outcomes

  1. Part 1- absence (or presence) of live female adult worms

    The absence (or presence) of live female adult worms, assessed by histological examination of nodules collected after nodulectomy

    Time frame: 12 months

  2. Part 1 - presence (or absence) of dead female adult worms

    The presence (or absence) of dead female adult worms, assessed by histological examination of nodules collected after nodulectomy

    Time frame: 12 months

  3. Part 1 - Absence (or presence) of skin microfilariae

    Absence (or presence) of skin microfilariae

    Time frame: up to 12 months

  4. Part 1 - reduction in skin microfilarial density

    The reduction in skin microfilarial density, defined as the mean number of microfilariae per milligram per subject, at all time-points after treatment related to baseline: change and percentage reduction

    Time frame: up to 12 months

  5. Part 1 - Absence (or presence) of microfilariae in nodular tissue

    The absence (or presence) of microfilariae in nodular tissue assessed by histological examination of nodules collected after nodulectomy

    Time frame: 12 months

  6. Part 2 - Absence (or presence) of live female adult worms with normal embryogenesis

    Absence (or presence) of live female adult worms with normal embryogenesis assessed by histological examination of nodules collected after nodulectomy.

    Time frame: 24 months

  7. Part 2 - Absence (or presence) of live female adult worms

    Absence (or presence) of live female adult worms, assessed by histological examination of nodules collected after nodulectomy

    Time frame: 24 months

  8. Part 2 - Presence (or absence) of dead female adult worms

    Presence (or absence) of dead female adult worms, assessed by histological examination of nodules collected after nodulectomy

    Time frame: 24 months

  9. Part 2 - Absence (or presence) of skin microfilariae

    Absence (or presence) of skin microfilariae

    Time frame: up to 24 months

  10. Part 2 - The reduction in skin microfilarial density

    The reduction in skin microfilarial density, defined as the mean number of microfilariae per milligram per subject, at all time-points after treatment related to baseline: change and percentage reduction

    Time frame: up to 24 months

  11. Part 2 - Absence (or presence) of microfilariae in nodular tissue

    The absence (or presence) of microfilariae in nodular tissue, assessed by histological examination of nodules collected on nodulectomy

    Time frame: 24 months

07

Study locations

3 sites
  • Centre de santé de référence de Kimpese
    Kimpese, Kongo Central, Congo, The Democratic Republic of the
  • Hôpital général de référence de Masimanimba
    Masi-Manimba, Kwilu, Congo, The Democratic Republic of the
  • University of Health and Allied Services School of Public Health
    Hohoe, Volta Region, Ghana
08

References and documents

Individual participant data

Plan to share: Yes — Summary results will be shared once Clinical Study Report will be available

Supporting information: Study protocol

Time frame: Within 12 months of Clinical Study report finalization

Access criteria: Open Access

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Sep 2026, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Jan 6, 2022
StartActual
Aug 30, 2021
Primary completionEst.
Sep 18, 2026
CompletionEst.
Oct 2, 2026
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180461
Lead sponsor
Drugs for Neglected Diseases
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Aug 30, 2021
Primary completion
Sep 18, 2026 (estimated)
Completion
Oct 2, 2026 (estimated)
Last update
Mar 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emodepside

Start the discussion